Polpharma And MSN Labs Team Up On Distribution

Polpharma has struck a deal with MSN Laboratories that will see the Polish generics player distribute the Indian firm’s hospital portfolio in Poland.

Polpharma has announced a collaboration with Indian player MSN Laboratories that will see the Polish firm distribute MSN’s hospital portfolio in its home market.

Billing itself as “the leader of the Polish pharmaceutical sector,” Polpharma said it was “delighted to announce a strategic distribution...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

Type:DisclosureDevelopments | Publication:GB | Section:Business | Paywall:Free — Article containing all Composer content for testing (Do not update)

 
• By 

Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.

ADHD

This is regarding ADHD.

GB-Business-Free-DisclosureDevelopments-The Secret to Walking More: It’s Not Counting Steps

 
• By 

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

GB-Business-Free-Podcast-The Secret to Walking More: It’s Not Counting Steps

 
• By 

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

More from Value Added Medicines

GB-Products-Premium-DataArticle (Tableau): Generics Bulletin’s Top 50 Ranking For 2024

 
• By 

This article compiles all of the data from Generics Bulletin’s 2024 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.